0001104659-22-089030.txt : 20220811 0001104659-22-089030.hdr.sgml : 20220811 20220811080554 ACCESSION NUMBER: 0001104659-22-089030 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20220811 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20220811 DATE AS OF CHANGE: 20220811 FILER: COMPANY DATA: COMPANY CONFORMED NAME: NeuBase Therapeutics, Inc. CENTRAL INDEX KEY: 0001173281 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 465622433 STATE OF INCORPORATION: DE FISCAL YEAR END: 0930 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-35963 FILM NUMBER: 221153772 BUSINESS ADDRESS: STREET 1: 700 TECHNOLOGY DRIVE CITY: PITTSBURGH STATE: PA ZIP: 15219 BUSINESS PHONE: 6464501790 MAIL ADDRESS: STREET 1: 700 TECHNOLOGY DRIVE CITY: PITTSBURGH STATE: PA ZIP: 15219 FORMER COMPANY: FORMER CONFORMED NAME: Ohr Pharmaceutical Inc DATE OF NAME CHANGE: 20090819 FORMER COMPANY: FORMER CONFORMED NAME: BBM HOLDINGS, INC. DATE OF NAME CHANGE: 20070402 FORMER COMPANY: FORMER CONFORMED NAME: PRIME RESOURCE INC DATE OF NAME CHANGE: 20020513 8-K 1 tm2223169d1_8k.htm FORM 8-K
0001173281 false 0001173281 2022-08-11 2022-08-11 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

 

FORM 8-K

Current Report

Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

 

Date of report (Date of earliest event reported): August 11, 2022

 

NeuBase Therapeutics, Inc.

(Exact Name of Registrant as Specified in Its Charter)

 

Delaware   001-35963   46-5622433
(State or Other Jurisdiction
of Incorporation)
  (Commission
File Number)
  (I.R.S. Employer
Identification No.)

 

350 Technology Drive, Pittsburgh, PA   15219
(Address of Principal Executive Offices)   (Zip Code)

 

  (412) 763-3350  
  (Registrant’s Telephone Number, Including Area Code)  

 

  N/A  
  (Former Name or Former Address, if Changed Since Last Report)  

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

  

¨Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class Trading Symbol(s) Name of each exchange on which registered
Common Stock, par value $0.0001 per share NBSE The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR § 230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR § 240.12b-2).

 

Emerging growth company ¨

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

 

 

 

 

 

Item 2.02. Results of Operations and Financial Condition.

 

On August 11, 2022, NeuBase Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the fiscal quarter ended June 30, 2022, and provided a corporate update. A copy of the press release is furnished as Exhibit 99.1 to this Current Report.

 

In accordance with General Instructions B.2 of Form 8-K, the information in Item 2.02 of this Current Report on Form 8-K shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

 

Item 9.01. Financial Statements and Exhibits.

 

(d) Exhibits

 

Exhibit
Number
Description
99.1 Press Release, dated August 11, 2022, Reporting Fiscal Third Quarter 2022 Financial Results
104

Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

 

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  NEUBASE THERAPEUTICS, INC.
  (Registrant)
   
Date: August 11, 2022 By: /s/ Todd P. Branning
    Todd P. Branning
    Chief Financial Officer

 

 

 

EX-99.1 2 tm2223169d1_ex99-1.htm EXHIBIT 99.1

 

Exhibit 99.1

 

NeuBase Therapeutics Reports Business Update and Financial Results for the Third Quarter of Fiscal Year 2022

 

·Lead myotonic dystrophy type 1 (DM1) candidate continues to show promising preclinical data, including the pharmacokinetics (PK) and biodistribution data presented at the American Society of Gene and Cell Therapy (ASGCT) 25th Annual Meeting supporting a differentiated whole-body treatment solution for DM1
·Management decision to conduct additional preclinical studies expected to further strengthen the planned Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA), expected to be submitted in mid-calendar year (CY) 2023
·On track to nominate a development candidate and initiate scale-up and toxicology activities for a systemically administered, allele-selective candidate for the Huntington’s disease (HD) program in CY2022
·Company expects to present preclinical data for the HD program at upcoming scientific conferences

 

PITTSBURGH and CAMBRIDGE, Mass., August 11, 2022 – NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (“NeuBase” or the “Company”), a biotechnology platform company Drugging the Genome™ to address disease at the base level using a new class of precision genetic medicines, today reported its financial results for the three-month period ended June 30, 2022, and other recent developments.

 

“Thus far in 2022, we have generated new data that strengthens application of the PATrOLTM platform and its potential to output novel genetic medicines that are broadly biodistributed after systemic routes of administration and engage double-stranded nucleic acid targets in the nucleus to resolve gene dysfunction. This includes new PK and biodistribution data for our DM1 development candidate, which were presented at the ASGCT 25th Annual Meeting, that support a differentiated whole-body solution for DM1 patients,” said Dietrich A. Stephan, Ph.D., Founder, Chief Executive Officer, and Chairman of NeuBase. “The data in each tissue we evaluated also displayed an extended elimination phase with tissue concentrations measurable for at least four weeks following a single intravenous (IV) dose administration and consistent with the durable pharmacology in the transgenic animal models. With these data in hand, we decided to perform additional IND-enabling studies to further characterize our development candidate and confirm our expectations of safety and efficacy. While conducting these additional studies will require us to push our guidance on the timing for our DM1 IND filing to mid-CY2023, patient safety and benefit are of utmost importance to us. We also believe the information that will be generated by these studies will benefit not only our DM1 program but all of our programs and better prepare us to enter the clinic and fulfill our mission of delivering new medicines to patients who currently have no therapeutic options.”

 

Dr. Stephan continued, “We continue to generate positive data from other programs in our pipeline, including in HD, that support the ability of the PATrOLTM platform to develop differentiated genetic medicines. We are confident in the ability of our platform and team to advance these drug candidates to clinical trials, and we look forward to providing further updates on our progress.”

 

Third Quarter of Fiscal Year 2022 and Recent Operating Highlights

 

·Myotonic Dystrophy Type 1 (DM1) Program: NeuBase is making steady progress advancing IND-enabling studies for its development candidate in the DM1 program, which includes PK, absorption, distribution, metabolism, and excretion (ADME), and bioavailability via IV and subcutaneous routes of administration, exploratory and IND-enabling Good Laboratory Practice (GLP) toxicology, and mechanism of action studies. In addition, Good Manufacturing Practice (GMP) of NeuBase’s development candidate to support Phase 1/2 clinical trials has been successfully implemented via contract manufacturing organizations.

 

oIn May 2022, the Company presented preclinical PK and biodistribution data at the ASGCT 25th Annual Meeting for its lead development candidate, NT-0231.F, supporting a differentiated whole body treatment solution for DM1. Following a single IV injection of 30 mg/kg in wild-type BALB/c mice, NT-0231.F was cleared rapidly from the systemic compartment and demonstrated rapid and wide distribution into tibialis anterior muscle, heart muscle, and brain tissues. NT-0231.F rapidly cleared the plasma, and each tissue evaluated displayed an extended elimination phase with tissue concentrations measurable for at least four weeks following a single IV dose administration.

 

oCompleted exploratory toxicology work in non-human primates and rats.

 

oInitiated a collaboration with Inserm to further study NT-0231.F using the DMSXL mouse model to measure central nervous system and heart pharmacology and to refine the human equivalent dose.

 

 

 

 

oCommitted to support the Myotonic Dystrophy Clinical Research Network, the world’s largest patient organization focused solely on myotonic dystrophy.

 

oThe Company expects to submit an IND application to the FDA for NT-0231.F in mid-CY2023.

 

·Huntington’s Disease (HD) Program: Preclinical development activities in the Company’s HD program progressed during the second quarter of CY2022. During the second half of CY2022, NeuBase expects to present new preclinical data at upcoming scientific conferences describing the pharmacology of a candidate compound in the brain after systemic administration, nominate a development candidate, and initiate scale-up and toxicology activities.

 

·KRAS Oncology Program: The Company continued in vitro mechanistic studies and in vivo pharmacology studies for the KRAS program (KRAS G12V and G12D mutations) to support the development of an allele-selective approach to engaging mutant KRAS at the DNA and RNA levels.

 

·Management Update: William (Bill) Mann, Ph.D. was promoted to President of the Company. Dr. Mann continues to serve as NeuBase’s Chief Operating Officer.

 

Financial Results for the Third Fiscal Quarter Ended June 30, 2022

 

·As of June 30, 2022, the Company had cash and cash equivalents of approximately $29.8 million, compared with approximately $52.9 million as of September 30, 2021.

 

·For the fiscal quarter ended June 30, 2022, the Company reported a net loss of approximately $8.5 million, or a net loss of $0.26 per share, compared with a net loss of approximately $8.7 million, or a net loss of $0.29 per share, for the same period last year.

 

·For the fiscal quarter ended June 30, 2022, total operating expenses were approximately $8.4 million, consisting of approximately $3.6 million in general and administrative expenses and $4.8 million of research and development expenses. This compares with total operating expenses of approximately $8.8 million for the same period last year, consisting of approximately $3.5 million in general and administrative expenses and $5.3 million in research and development expenses.

 

Financial Results for the Nine-Month Period Ended June 30, 2022

 

·For the nine-month period ended June 30, 2022, the Company reported a net loss of approximately $26.1 million, or a net loss of $0.80 per share, compared with a net loss of approximately $18.3 million, or a net loss of $0.72 per share, for the same period last year.

 

·For the nine-month period ended June 30, 2022, total operating expenses were approximately $25.6 million, consisting of approximately $9.6 million in general and administrative expenses and $16.0 million of research and development expenses. This compares with total operating expenses of approximately $19.4 million for the same period last year, consisting of approximately $8.8 million in general and administrative expenses and $10.6 million in research and development expenses.

 

About NeuBase Therapeutics

 

NeuBase is accelerating the genetic revolution by developing a new class of precision genetic medicines that Drug the Genome™. The Company’s therapies are built on a proprietary platform called PATrOL™ that encompasses a novel peptide-nucleic acid antisense oligonucleobase technology combined with a novel delivery shuttle that overcome many of the hurdles to selective mutation engagement, repeat dosing, and systemic delivery of genetic medicines. With an initial focus on silencing disease-causing mutations in debilitating neurological, neuromuscular, and oncologic disorders, NeuBase is committed to redefining medicine for the millions of patients with both common and rare conditions, who currently have limited to no treatment options. To learn more, visit www.neubasetherapeutics.com.

 

Use of Forward-Looking Statements

 

This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act. These forward-looking statements are distinguished by use of words such as "will," "would," "anticipate," "expect," "believe," "designed," "plan," or "intend," the negative of these terms, and similar references to future periods. These forward-looking statements include, among others, those related to the potential and prospects of the Company’s proprietary PATrOL™ platform, DM1, HD and KRAS programs, including the plan to provide updates to the HD program at scientific conferences in CY2022 and the Company’s expectation that it will submit an IND application for the DM1 program to the U.S. Food and Drug Administration in the middle of CY2023. These views involve risks and uncertainties that are difficult to predict and, accordingly, our actual results may differ materially from the results discussed in our forward-looking statements. Our forward-looking statements contained herein speak only as of the date of this press release. Factors or events that we cannot predict, including those risk factors contained in our filings with the U.S. Securities and Exchange Commission, may cause our actual results to differ from those expressed in forward-looking statements. The Company may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in the forward-looking statements, and you should not place undue reliance on these forward-looking statements. Because such statements deal with future events and are based on the Company's current expectations, they are subject to various risks and uncertainties, and actual results, performance or achievements of the Company could differ materially from those described in or implied by the statements in this press release, including: the Company's plans to develop and commercialize its product candidates; the timing of initiation of the Company's planned clinical trials; the risks that prior data will not be replicated in future studies; the timing of any planned investigational new drug application or new drug application; the Company's plans to research, develop and commercialize its current and future product candidates; the clinical utility, potential benefits and market acceptance of the Company's product candidates; the Company's commercialization, marketing and manufacturing capabilities and strategy; global health conditions, including the impact of COVID-19; the Company's ability to protect its intellectual property position; and the requirement for additional capital to continue to advance these product candidates, which may not be available on favorable terms or at all, as well as those risk factors contained in our filings with the U.S. Securities and Exchange Commission. Except as otherwise required by law, the Company disclaims any intention or obligation to update or revise any forward-looking statements, which speak only as of the date hereof, whether as a result of new information, future events or circumstances or otherwise.

 

 

 

 

NeuBase Investor Contact:  NeuBase Media Contact:
Dan Ferry  Jessica Yingling, Ph.D.
Managing Director  Little Dog Communications Inc.
LifeSci Advisors, LLC  jessica@litldog.com
daniel@lifesciadvisors.com  OP: (858) 344-8091
OP: (617) 430-7576   

 

 

 

EX-101.SCH 3 nbse-20220811.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 nbse-20220811_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 5 nbse-20220811_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 6 R1.htm IDEA: XBRL DOCUMENT v3.22.2
Cover
Aug. 11, 2022
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Aug. 11, 2022
Entity File Number 001-35963
Entity Registrant Name NeuBase Therapeutics, Inc.
Entity Central Index Key 0001173281
Entity Tax Identification Number 46-5622433
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 350 Technology Drive
Entity Address, City or Town Pittsburgh
Entity Address, State or Province PA
Entity Address, Postal Zip Code 15219
City Area Code 412
Local Phone Number 763-3350
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, par value $0.0001 per share
Trading Symbol NBSE
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
XML 7 tm2223169d1_8k_htm.xml IDEA: XBRL DOCUMENT 0001173281 2022-08-11 2022-08-11 iso4217:USD shares iso4217:USD shares 0001173281 false 8-K 2022-08-11 NeuBase Therapeutics, Inc. DE 001-35963 46-5622433 350 Technology Drive Pittsburgh PA 15219 412 763-3350 false false false false Common Stock, par value $0.0001 per share NBSE NASDAQ false EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.2 html 1 22 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://neubasetherapeutics.com/role/Cover Cover Cover 1 false false All Reports Book All Reports tm2223169d1_8k.htm nbse-20220811.xsd nbse-20220811_lab.xml nbse-20220811_pre.xml tm2223169d1_ex99-1.htm http://xbrl.sec.gov/dei/2021q4 true false JSON 13 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "tm2223169d1_8k.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "tm2223169d1_8k.htm" ] }, "labelLink": { "local": [ "nbse-20220811_lab.xml" ] }, "presentationLink": { "local": [ "nbse-20220811_pre.xml" ] }, "schema": { "local": [ "nbse-20220811.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd" ] } }, "elementCount": 59, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021q4": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 22, "memberCustom": 0, "memberStandard": 0, "nsprefix": "NBSE", "nsuri": "http://neubasetherapeutics.com/20220811", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "p", "body", "html" ], "baseRef": "tm2223169d1_8k.htm", "contextRef": "From2022-08-11to2022-08-11", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "role": "http://neubasetherapeutics.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "body", "html" ], "baseRef": "tm2223169d1_8k.htm", "contextRef": "From2022-08-11to2022-08-11", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://neubasetherapeutics.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://neubasetherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://neubasetherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://neubasetherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://neubasetherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://neubasetherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://neubasetherapeutics.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://neubasetherapeutics.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r11", "r13", "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://neubasetherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://neubasetherapeutics.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://neubasetherapeutics.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://neubasetherapeutics.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://neubasetherapeutics.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://neubasetherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://neubasetherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://neubasetherapeutics.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://neubasetherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://neubasetherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://neubasetherapeutics.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://neubasetherapeutics.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://neubasetherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://neubasetherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://neubasetherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://neubasetherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://neubasetherapeutics.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://neubasetherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://neubasetherapeutics.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://neubasetherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://neubasetherapeutics.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://neubasetherapeutics.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://neubasetherapeutics.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://neubasetherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://neubasetherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://neubasetherapeutics.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://neubasetherapeutics.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://neubasetherapeutics.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://neubasetherapeutics.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://neubasetherapeutics.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://neubasetherapeutics.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://neubasetherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://neubasetherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://neubasetherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://neubasetherapeutics.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://neubasetherapeutics.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://neubasetherapeutics.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://neubasetherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://neubasetherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://neubasetherapeutics.com/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://neubasetherapeutics.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://neubasetherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://neubasetherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://neubasetherapeutics.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://neubasetherapeutics.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://neubasetherapeutics.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://neubasetherapeutics.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://neubasetherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://neubasetherapeutics.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://neubasetherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r10": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r11": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" }, "r12": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r13": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r14": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r15": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r16": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r17": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405" }, "r18": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r19": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r9": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d" } }, "version": "2.1" } ZIP 14 0001104659-22-089030-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001104659-22-089030-xbrl.zip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